The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

For example, a 2022 study of tirzepatide (the active ingredient in Mounjaro) prescribed for obesity included people with an average weight of 231 lb. After 18 months, participants on the lowest ...

Mounjaro (tirzepatide) is a prescription drug that’s used to treat type 2 diabetes. The drug comes as a liquid solution that you inject under your skin, typically once per week. Mounjaro ...

In terms of drug sales buoying those company rankings, Lilly’s tirzepatide drugs and Novo’s semaglutide franchise are expected to reel in more than $70 billion in combined sales this year.

Shortly after the OFA filed its lawsuit, the FDA said it would review its decision to remove Lilly’s tirzepatide products from its shortage list—though the agency ultimately stuck by its ...

Neu­ro­science drug de­vel­op­er Neumo­ra Ther­a­peu­tics re­leased high­ly an­tic­i­pat­ed re­sults from the first of three Phase 3 tri­als for its ex­per­i­men­tal ma­jor … ...

Weight-loss injection Mounjaro, also known as tirzepatide, will be rolled out on the NHS gradually over a 12-year period, starting this year, but many eligible patients will have to wait. Professor ...

Weight-loss injection Mounjaro, also known as tirzepatide, will be rolled out on the NHS gradually over a 12-year period, starting this year, but many eligible patients will have to wait.

According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...